文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

2023年浙江省治疗前HIV-1耐药谱及分子传播网络特征

Pre-treatment HIV-1 drug resistance spectrum and molecular transmission network characteristics in Zhejiang Province, 2023: implications for targeted control of drug-resistant HIV transmission.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究对浙江省3466例新诊断未治疗HIV-1感染者进行横断面分子流行病学分析,治疗前耐药(PDR)总患病率为6.95%(95%CI:6.11%-7.80%),以NNRTI耐药为主,42.32%的PDR病例聚集于51个耐药传播簇,提示需加强监测和簇靶向干预。

要点

  • 浙江省2023年PDR总患病率为6.95%,金华最高(10.02%)。
  • NNRTI耐药最常见(67.66%),主要突变K103N/S(46.47%)。
  • 42.32%的PDR病例成簇,18个中/大簇携带高水平NNRTI耐药。

核心结论

  • 浙江省PDR以NNRTI耐药为主,存在明显的区域性聚集和推测的传播网络。
  • 亟需扩大标准化PDR监测、优化一线ART方案并实施簇靶向干预。

研究设计与样本

  • 全省横断面分子流行病学研究中,扩增HIV-1 pol基因并进行Sanger测序。
  • 共纳入3466条有效pol序列,使用Stanford HIV耐药数据库解读基因型耐药,以0.01替换/位点为阈值推断传播网络。

主要发现

  • 共识别241例PDR,总患病率6.95%(95%CI:6.11%-7.80%),金华最高(10.02%,95%CI:7.39%-12.65%)。
  • 241例PDR中检出10种亚型,以CRF07_BC(43.57%,105/241)和CRF01_AE(38.17%,92/241)为主。
  • NNRTI耐药最常见(67.66%,159/235),主要耐药突变为K103N/S(46.47%,112/241)。
  • 高水平耐药以奈韦拉平(63.07%,152/241)和依非韦伦(54.77%,132/241)最高。
  • 42.32%的PDR病例聚集于51个耐药传播簇,其中18个中/大簇(≥4人)携带高水平NNRTI耐药,8个簇平均成对距离≤0.005替换/位点。

临床怎么用

  • 应加强治疗前耐药监测,尤其关注NNRTI耐药高发地区。
  • 根据PDR谱优化一线ART方案选择。
  • 针对耐药传播簇实施靶向干预以阻断传播。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the epidemiology, subtype distribution and transmission dynamics of pre-treatment drug resistance (PDR) among newly diagnosed antiretroviral therapy (ART)-naive individuals with human immunodeficiency virus type 1 (HIV-1) in Zhejiang Province, Eastern China, in 2023. METHODS: In this province-wide cross-sectional molecular epidemiological study, the HIV-1 pol gene was amplified and Sanger-sequenced. Genotypic resistance was interpreted using the Stanford HIV Drug Resistance Database, subtypes were assigned by phylogenetic analysis, and transmission networks were inferred at a pairwise genetic distance threshold of 0.01 substitutions/site, with sensitivity analysis across 0.001-0.015 substitutions/site thresholds. RESULTS: Among 3466 valid pol sequences, 241 PDR cases were identified, yielding an overall PDR prevalence of 6.95% [95% confidence interval (CI): 6.11%-7.80%], with the highest prevalence observed in Jinhua (10.02%; 95% CI: 7.39%-12.65%). Of the 241 PDR cases, 10 distinct HIV-1 subtypes were detected, among which CRF07_BC (43.57%, 105/241) and CRF01_AE (38.17%, 92/241) predominated. Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance was most frequent (67.66%, 159/235), driven by the resistance-associated mutation (RAM) K103N/S (46.47%, 112/241); high-level resistance was highest for nevirapine (63.07%, 152/241) and efavirenz (54.77%, 132/241). Overall, 42.32% of PDR cases clustered into 51 resistance-associated transmission clusters (RTCs); 18 medium/large RTCs (≥4 individuals) carried high-level NNRTI resistance, 8 with mean pairwise distances ≤0.005 substitutions/site, suggesting high sequence homology and suggestive of close epidemiological linkage among clustered strains. CONCLUSIONS: In this study, PDR cases in Zhejiang were dominated by NNRTI resistance with substantial regional clustering, indicating putative transmission networks. Scaled-up standardized PDR surveillance, optimized first-line ART regimens and cluster-targeted interventions are urgently needed to curb resistant HIV-1 transmission and inform national HIV drug resistance policy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Fan Q, Zhang J, Jiang J, et al. Pre-treatment HIV-1 drug resistance spectrum and molecular transmission network characteristics in Zhejiang Province, 2023: implications for targeted control of drug-resistant HIV transmission. J Antimicrob Chemother. 2026. PMID: 42788690. doi:10.1093/jac/dkag299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。